Fred Hutchinson Cancer Research Center, Seattle, WA.
Blood. 2017 Nov 30;130(22):2373-2376. doi: 10.1182/blood-2017-09-797712. Epub 2017 Oct 11.
On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33 acute myeloid leukemia and for patients aged ≥2 years with CD33 acute myeloid leukemia who have experienced a relapse or who have not responded to initial treatment. This signals a new chapter in the long and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FDA.
2017 年 9 月 1 日，美国食品和药物管理局（FDA）批准吉妥珠单抗奥佐米星（GO）用于治疗新诊断的 CD33 急性髓系白血病的成人患者，以及年龄≥2 岁的 CD33 急性髓系白血病患者，这些患者经历了复发或对初始治疗没有反应。这标志着 GO 的漫长而不寻常故事的新篇章，GO 是 FDA 批准的第一个用于人类的抗体-药物偶联物。
